Сентябрь/Октябрь 2014, том 6, номер 2

<<< Вернуться к содержанию

■ Клинические рекомендации

Майданник В.Г. Клинические рекомендации по диагностике и лечению метаболического синдрома и ожирения у детей и подростков. Международный журнал педиатрии, акушерства и гинекологии. 2014;Т6(2):39-55

Клинические рекомендации по диагностике и лечению метаболического синдрома и ожирения у детей и подростков

Майданник В.Г.

Национальный медицинский университет имени А.А. Богомольца, Киев, Украина

■ Резюме:

■ Ключевые слова:

дети, метаболический синдром, ожирение, диагностика, лечение

■ Литература:

1. Sarafidis P.A., Nilsson P.M. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24(4):621–626.

1а. Lee L., Sanders R.A. Metabolic syndrome. Pediatr Rev. 2012; 33(10):459-466.

2. Hanefeld M., Leonhardt W. Das metabolische syndrom. Dtsch Gesundheitsw. 1981; 36:545–551.

3. Kylin E. Hypertonie-hyperglykamie-hyperurikamiesyndrome. Zentralbl Innere Med. 1921;42:873–877.

4. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.

5. Kaplan N.M. The deadly quartet. Upperbody obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514–1520.

6. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553.

7. Alberti K.G., Eckel R.H., Grundy S.M. et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.

8. Moran A., Jacobs D.R. Jr, Steinberger J. et al. Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation. 2008;117(18): 2361–2368.

9. Dai S., Fulton J.E., Harrist R.B. et al. Blood lipids in children: age-related patterns and association with body-fat indices: Project Heart-Beat Am J Prev Med. 2009;37(1 Suppl):S56–S64

10. Steinberger J., Daniels S.R., Eckel R.H. et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2009;119(4): 628–647.

11. Zimmet P., Alberti K.G., Kaufman F. et al. IDF Consensus Group. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes.2007;8(5):299–306.

12. Cook S., Auinger P., Li C., Ford E.S. Metabolic syndrome rates in united states adolescents, from the national health and nutrition examination survey, 1999-2002. J Pediatr. 2008;152(2):165–170.

13. Goodman E., Daniels S.R., Morrison J.A. et al. Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. J Pediatr. 2004;145(4):445–451.

14. de Ferranti S.D., Gauvreau K., Ludwig D.S. et al. Prevalence of the metabolic syndrome in American adolescents: findings from the third national health and nutrition examination survey. Circulation. 2004;110(16):2494–2497.

15. Deboer M.D. Underdiagnosis of metabolic syndrome in non-Hispanic black adolescents: a call for ethnic-specific criteria. Curr Cardiovasc Risk Rep. 2010;4(4):302–310.

16. Gustafson J.K., Yanoff L.B., Easter B.D. et al. The stability of metabolic syndrome in children and adolescents. J Clin Endocrinol Metab. 2009;94(12):4828–4834.

17. Goodman E., Daniels S.R., Meigs J.B., Dolan L.M. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation. 2007;115(17):2316–2322.

18. Wilson P.W., D’Agostino R.B., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112(20):3066–3072.

19. Kelishadi R., Cook S.R., Adibi A. et al. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents.Diabetol Metab Syndr. 2009;1:29.

20. Moran L.J., Misso M.L., Wild R.A., Norman R.J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–363.

21. Lam J.C., Ip M.S. Obstructive sleep apnea and the metabolic syndrome. Expert Rev Respir Med. 2009;3(2):177–186.

22. Bao W., Srinivasan S.R., Wattigney W.A., Berenson G.S. Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study. Arch Intern Med. 1994;154(16):1842–1847.

23. Morrison J.A., Friedman L.A., Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics. 2007;120(2):340–345.

24. Goodman E., Dolan L.M., Morrison J.A., Daniels S.R. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation. 2005;111(15):1970–1977.

25. Daniels S.R., Morrison J.A., Sprecher D.L. et al. Association of body fat distribution and cardiovascular risk factors in children and adolescents. Circulation. 1999;99(4):541–545.

26. Raitakari O.T., Juonala M., Kähönen M. et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290(17):2277–2283.

27. Magnussen C.G., Koskinen J., Chen W. et al. Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study. Circulation. 2010;122(16):1604–1611.

28. Tzou W.S., Douglas P.S., Srinivasan S.R. et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol. 2005;46(3):457–463.

29. Morrison J.A., Friedman L.A., Wang P., Glueck C.J. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr. 2008;152(2):201–206.

30. Nelson R.A., Bremer A.A. Insulin resistance and metabolic syndrome in the pediatric population. Metab Syndr Relat Disord. 2010;8(1):1–14.

31. Park Y.W., Zhu S., Palaniappan L., Heshka S. et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427–436.

32. Bajaj M., Defronzo R.A. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol. 2003;10(3):311–323.

33. Scaglione R., Di Chiara T., Cariello T., Licata G. Visceral obesity and metabolic syndrome: two faces of the same medal? Intern Emerg Med. 2010;5(2):111–119.

34. Bosy-Westphal A., Onur S., Geisler C. et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond). 2007;31(5):784–790.

35. Balletshofer B.M., Rittig K., Enderle M.D. et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101(15):1780–1784.

36. Tang W., Hong Y., Province M.A. et al. Familial clustering for features of the metabolic syndrome: the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study. Diabetes Care. 2006;29(3):631–636.

37. Bao W., Srinivasan S.R., Valdez R. et al. Longitudinal changes in cardiovascular risk from childhood to young adulthood in offspring of parents with coronary artery disease: the Bogalusa Heart Study. JAMA. 1997;278(21):1749–1754.

38. Pankow J.S., Jacobs D.R. Jr, Steinberger J. et al. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care. 2004;27(3):775–780.

39. Svec F., Nastasi K., Hilton C. et al. Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes. 1992;41(3):313–317.

40. Batey L.S., Goff D.C. Jr, Tortolero S.R. et al. Summary measures of the insulin resistance syndrome are adverse among Mexican-American versus non-Hispanic white children: the Corpus Christi Child Heart Study. Circulation. 1997;96(12):4319–4325.

41. Ogden C.L., Carroll M.D., Curtin L.R. et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010;303(3):242–249.

42. Walker S.E., Gurka M.J., Oliver M.N. et al. Racial/ethnic discrepancies in the metabolic syndrome begin in childhood and persist after adjustment for environmental factors. Nutr Metab Cardiovasc Dis.2012;22(2):141–148.

43. Chen W., Srinivasan S.R., Elkasabany A., Berenson G.S. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol. 1999;150(7): 667–674.

44. Weiss R., Dziura J., Burgert T.S. et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med.2004;350(23):2362–2374.

45. US Department of Health and Human Services. Physical activity and health: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. MMWR (Morb Mortal Wkly Rep). 1996;45(27):591–592.

46. Schmitz K.H., Jacobs D.R. Jr, Hong C.P. et al. Association of physical activity with insulin sensitivity in children. Int J Obes Relat Metab Disord. 2002;26(10):1310–1316.

47. Bremer A.A., Auinger P., Byrd R.S. Relationship between insulin resistance-associated metabolic parameters and anthropometric measurements with sugarsweetened beverage intake and physical activity levels in US adolescents: findings from the 1999-2004 National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2009;163(4):328–335.

48. Farpour-Lambert N.J., Aggoun Y., Marchand L.M. et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol. 2009;54 (25):2396–2406.

49. Balducci S., Zanuso S., Nicolucci A. et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss.Nutr Metab Cardiovasc Dis. 2010;20(8):608–617.

50. Rubin D.A., Hackney A.C. Inflammatory cytokines and metabolic risk factors during growth and maturation: influence of physical activity. Med Sport Sci. 2010;55:43–55.

51. Weitzman M., Cook S., Auinger P. et al. Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation. 2005;112(6):862–869.

52. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15(3):318–368.

53. Rexrode K.M., Manson J.E., Hennekens C.H. Obesity and cardiovascular disease. Curr Opin Cardiol. 1996;11(5):490–495.

54. Björntorp P. Abdominal fat distribution and disease: an overview of epidemiological data. Ann Med. 1992;24(1):15–18.

55. Neovius M., Rasmussen F.. Evaluation of BMI-based classification of adolescent overweight and obesity: choice of percentage body fat cutoffs exerts a large influence. The COMPASS study. Eur J Clin Nutr. 2008;62(10):1201–1207.

56. Hall D.M., Cole T.J. What use is the BMI? Arch Dis Child. 2006;91(4):283–286.

57. Bonora E., Micciolo R., Ghiatas A.A. et al. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Metabolism. 1995;44(12):1617–1625.

58. Lee S., Bacha F., Gungor N., Arslanian S.A. Waist circumference is an independent predictor of insulin resistance in black and white youths. J Pediatr. 2006;148(2):188–194.

59. Maffeis C., Pietrobelli A., Grezzani A. et al. Waist circumference and cardiovascular risk factors in prepubertal children. Obes Res. 2001;9(3):179–187.

60. Barlow S.E.; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(suppl 4):S164–S192.

60а. Майданник В.Г., Хайтович М.В., Павлишин Г.А. та ін. Поширеність надлишкової маси тіла та підвищеного артеріального тиску серед школярів різних регіонів України. Межд. журн. педиатр., акуш. и гинекол. 2013; 3(1): 33-39.

61. Freedman D.S., Dietz W.H., Srinivasan S.R., Berenson G.S. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics. 1999;103(6 pt 1):1175–1182.

62. Meshkani R., Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 2009;42(13-14):1331–1346.

63. Adiels M., Olofsson S.O., Taskinen M.R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225–1236.

64. Kwiterovich P.O. Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002;90(8A):30i–47i.

65. Rainwater D.L., Mitchell B.D., Comuzzie A.G., Haffner S.M. Relationship of low-density lipoprotein particle size and measures of adiposity. Int J Obes Relat Metab Disord. 1999;23(2):180–189.

66. Kang H.S., Gutin B., Barbeau P. et al. Low-density lipoprotein particle size, central obesity, cardiovascular fitness, and insulin resistance syndrome markers in obese youths. Int J Obes Relat Metab Disord. 2002;26(8):1030–1035.

67. Ferrannini E., Buzzigoli G., Bonadonna R. et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317(6): 350–357.

68. Natali A., Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33(2):417–429.

69. Scherrer U., Randin D., Vollenweider P. et al. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest. 1994;94(6): 2511–2515.

70. DeFronzo R.A., Cooke C.R., Andres R. et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55(4):845–855.

71. Barbato A., Cappuccio F.P., Folkerd E.J. et al. Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia. 2004;47(1):40–46.

72. Anderson E.A., Hoffman R.P., Balon T.W. et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87(6):2246–2252.

73. Egan B.M. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep. 2003;5(3):247–254.

74. Tripathy D., Mohanty P., Dhindsa S. et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52(12): 2882–2887.

75. Sinaiko A.R., Steinberger J., Moran A. et al. Relation of insulin resistance to blood pressure in childhood. J Hypertens. 2002;20(3):509–517.

76. Göke B. Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance. Diabetes Res Clin Pract. 1998;40(suppl):S15–S20.

77. Dolan L.M., Bean J., D’Alessio D. et al. Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. J Pediatr. 2005; 146(6):751–758.

78. Weiss R., Dufour S., Taksali S.E. et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003;362(9388):951–957.

79. Weiss R., Taksali S.E., Tamborlane W.V. et al. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005;28(4):902–909.

80. Fagot-Campagna A., Pettitt D.J., Engelgau M.M. et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5):664–672.

81. Ode K.L., Frohnert B.I., Nathan B.M. Identification and treatment of metabolic complications in pediatric obesity. Rev Endocr Metab Disord. 2009;10(3):167–188.

82. Sutherland J.P., McKinley B., Eckel R.H. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004;2(2):82–104.

83. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49(21):2129–2138.

84. Abd T.T., Eapen D.J., Bajpai A. et al. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr Atheroscler Rep. 2011;13(2):154–161.

85. Moran A., Steffen L.M., Jacobs D.R. Jr et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care. 2005;28 (7):1763–1768.

86. Wärnberg J., Marcos A. Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr Opin Lipidol. 2008;19(1):11–15.

87. Greenberg A.S., McDaniel M.L. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;32(suppl 3):24–34.

88. Zawadzki J.K., Dunaif A. 1992 diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., Merriam G.R., eds. Polycystic Ovary Syndrome. Oxford, UK:Blackwell; 1992:56–69.

89. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

90. Coviello A.D., Legro R.S., Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91(2):492–497.

91. Cussons A.J., Watts G.F., Burke V. et al. Cardiometabolic risk in polycystic ovary syndrome:a comparison of different approaches to defining the metabolic syndrome. Hum Reprod. 2008;23(10):2352–2358.

92. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 suppl 1):S99–S112.

93. Fishbein M.H., Miner M., Mogren C., Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. JPediatr Gastroenterol Nutr. 2003;36(1):54–61.

94. Salamone F., Bugianesi E. Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. J Hepatol. 2010;53 (6):1146–1147.

95. Mencin A.A., Lavine J.E. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care. 2011;14(2):151–157.

96. Berenson G.S., Srinivasan S.R., Bao W. et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656.

97. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213–S256.

98. Kirk S., Zeller M., Claytor R. et al. The relationship of health outcomes to improvement in BMI in children and adolescents. Obes Res. 2005;13(5):876–882.

99. Hamman R.F., Wing R.R., Edelstein S.L. et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–2107.

100. Rome E.S. Obesity prevention and treatment. Pediatr Rev. 2011;32(9):363–372.

101. Ровда Ю.И., Миняйлова Н.Н., Казакова Л.М. Вопросы лечения и профилактики метаболического синдрома у детей и подростков. Педиатрия. 2010; 89(5):150-155.

102. Freemark M., Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4). Available at: www.pediatrics.org/cgi/content/full/107/4/e55.

103. Cali A.M., Pierpont B.M., Taksali S.E. et al. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study. Obesity (Silver Spring). 2011;19(1):94–99.

104.Леженко Г.А., Гладун К.В., Пашкова Е.Е. Факторы формирования артериальной гипертензии у детей с ожирением. Дитячий лікар. 2011; 3:23-34.

105.Toelg M. Снижение веса у детей и подростков. Здоровье ребенка. 2011; 2(29): http://www.mif-ua.com/archive/article/20642.

106. Хайтович Н.В., Майданник В.Г., Очеретько В.В. и др. Эффективность и безопасность цефамадара при лечении школьников с избыточной массой тела. Межд. журн. педиатр., акуш. и гинекол. 2013; 3(2): 63-66.